Resources
86 Results (showing 61 - 70)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 7/19/2021 (updated 4/2/2024)
Drug overdose deaths in the United States hit a record high in 2017, with an estimated 72,000 deaths. Over two-thirds of those deaths, roughly 47,600, were due to opioids.These staggering numbers continued in 2018, as over 67,000 drug overdose deaths occurred, and opioids were involved in rough 46,800 of those overdose deaths.
This roadmap highlights existing state efforts and serves as a policy development tool for Governors and state officials seeking to improve coordination and bolster existing efforts across state agencies to address OUD among people involved in the justice system by expanding access to evidence-based medications.
Posted 7/19/2021 (updated 4/2/2024)
Buprenorphine/naloxone, an evidence-based treatment for opioid use disorder, is sometimes diverted for non-medical use. In Rhode Island, the prevalence of opioid use and, more recently, of fentanyl in the illicit drug supply is driving overdose fatalities, which increases the need for treatment and raises questions about the changing role of diverted medication in shaping overdose risk.
Posted 7/28/2021 (updated 4/2/2024)
The most effective treatments for opioid use disorder (OUD) are the three prescription medications approved by the U.S. Food and Drug Administration (FDA)—methadone, buprenorphine, and naltrexone—that are proved to increase a patient’s treatment retention and reduce illicit use and the risk of overdose. The only facilities legally able to offer all three medications are opioid treatment programs (OTPs), a critical component of the U.S. substance use treatment system that are regulated by the federal Drug Enforcement Administration (DEA) and Substance Abuse and Mental Health Services Administration (SAMHSA), as well as state agencies, and are certified to administer any FDA-approved medication for the treatment of OUD.
Posted 8/4/2021 (updated 4/2/2024)
This session provided an opportunity to learn how to encourage faith leaders how to engage in harm reduction activities.
Posted 8/4/2021 (updated 4/2/2024)
Posted 8/25/2021 (updated 4/2/2024)
HRSA’s Health Centers Program published new research briefs exploring health center capacity in maternity care deserts, differences in clinical quality measures among Appalachian and non-Appalachian health centers, and the role of health centers in providing medication-assisted treatment. The briefs were developed through the UDS Mapper—a tool that helps evaluate the geographic reach, penetration, and growth of the Health Center Program and its relationship to other federally-linked health resources.
Posted 10/21/2020 (updated 4/3/2024)
This study sought to identify best practices for retaining individuals in treatment and for achieving continuity of care between settings.
Posted 10/23/2020 (updated 4/3/2024)
This report analyzes Medicaid State Drug Utilization Data from 2011 to 2018 to track Medicaid prescriptions, unit prices, and spending after accounting for federal rebates paid by manufactures to Medicaid programs for extended-release MOUDs.
Posted 11/18/2020 (updated 4/3/2024)
Pharmacists can play an important role in improving access to medication for opioid use disorder (MOUD), especially for individuals living in rural areas where health care workforce shortages are pervasive. Learn how pharmacists can provide Medication Administration Services (MAS) and establish Collaborative Practice Agreements (CPA) in coordination with one or more treating health care providers.
Posted 12/9/2020 (updated 4/3/2024)
State policymakers are interested in learning about the most effective treatments to address OUD and avoid unintended consequences such as overdose events, mortality from overdose, and use of illicit and unregulated drugs. This article describes the lack of evidence surrounding the use of Medically Supervised Withdrawal as a standalone “treatment.”